Advanced Solid Tumor, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer
Conditions
Keywords
TIGIT inhibitor, PD-1 inhibitor, Advanced Solid Tumor
Brief summary
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous \[NSCLC-NS\] and Hepatocellular carcinoma \[HCC\])
Detailed description
The Dose Optimization phase will enroll participants with advanced/metastatic solid tumors (except pancreatic). Up to 20 participants will be randomized into two dosing arms. Two different primary advanced solid tumors have been selected for investigation of antitumor activity in the Indication-specific Expansion phase. Up to 40 participants will be enrolled into each Indication-specific Expansion phase cohort. All participants in both phases will receive CHS-006 in combination with toripalimab intravenously (IV) every 3 weeks (Q3W).
Interventions
DRUGCHS-006 (anti-TIGIT)
Arm A participants will receive CHS-006 administered via IV Q3W.
DRUGtoripalimab (anti-PD-1)
Arm B participants will receive toripalimab administered via IV Q3W.
Sponsors
Medpace, Inc.
Shanghai Junshi Bioscience Co., Ltd.
Coherus Oncology, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a Phase 1, open-label, multiple-phase, multiple phase study. Participants within the advanced solid tumor dose optimization phase will be assigned to one of two dosing arms. After one CHS-006 dose has been selected from Phase 1, Phase 2 participants will be dosed with that dose in combination with toripalimab.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males and females, ≥18 years old; * Histopathologically or cytologically confirmed advanced solid tumor (except pancreatic) with disease progression after at least 1 prior line of standard therapy (Dose Optimization phase); * Tumor-specific criteria (Indication-specific Expansion phase): * NSCLC-NS (without sensitizing EGFR/ALK/ROS-1/MET mutations) 2nd line plus (2L+): has received and progressed on at least 1 prior chemotherapy regimen. Prior treatment with both anti-PD-1 therapy and platinum-based chemotherapy either concurrently or sequentially are eligible. * Hepatocellular carcinoma (HCC) 2L+: has received and progressed on at least 1 prior anticancer regimen. Participants with prior treatment with an anti-PD-1 or PD-L1 agent are eligible. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and expected survival ≥12 weeks; * At least 1 measurable lesion per RECIST v1.1; * Adequate organ and marrow function
Exclusion criteria
* Current or prior use of systemic anticancer therapy, including but not limited to chemotherapy, immunotherapy, biologic therapy, hormone therapy, and targeted therapy, within 28 days prior to the 1st dose of CHS-006; * NSCLC participants with genomic mutations (e.g., EGFR, ALK, ROS-1, MET, etc.) for which FDA-approved targeted therapies are available or require progression on appropriate prior to enrollment; * Prior exposure to monoclonal antibodies (mAbs) targeting TIGIT or any of its ligands, including CD155, CD112, or CD113; * Major surgery within 28 days prior to the 1st dose of CHS-006 or still recovering from prior surgery; * Symptomatic or untreated central nervous system (CNS) metastases; * Use of therapeutic immunosuppressive medication within 28 days prior to the 1st planned dose of CHS-006; * Receipt of live, attenuated vaccination within 30 days prior to the 1st dose of CHS- 006; * History of active autoimmune disease within the past 2 years, with the following exceptions: vitiligo, alopecia, endocrinopathies controlled by hormone replacement therapy, rheumatoid arthritis and other arthropathies that have not required immunosuppression other than nonsteroidal anti-inflammatory agents, celiac disease controlled by diet, or psoriasis controlled with topical medication; * Participants with another active solid tumor that has not been curatively treated.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab | Day 1 of study treatment through up to 90 days post last dose of study treatment | Assessed by number of participants with TEAEs assessed by the investigator as per CTCAE v5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of CHS-006 and/or toripalimab | Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment | Percentage of participants who develop treatment-emergent antidrug antibodies (ADA) to CHS-006 and/or toripalimab |
| Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by the investigator | Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study | Investigator-assessed ORR as per RECIST v1.1 |
| Duration of response (DoR) using RECIST v1.1 assessed by the investigator | Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study | Investigator-assessed DoR as per RECIST v1.1 |
| Description of the PK profile of CHS-006 in combination with toripalimab | Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment | Assessed by serum concentration of CHS-006 and toripalimab as determined by validated assays |
| Time to response (TTR) using RECIST v1.1 assessed by the investigator | Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study | Investigator-assessed TTR as per RECIST v1.1 |
| Progression-free survival (PFS) using RECIST v1.1 assessed by the investigator | Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study | Investigator-assessed PFS as per RECIST v1.1 |
| Overall survival (OS) using RECIST v1.1 assessed by the investigator | Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study | Investigator-assessed PFS as per RECIST v1.1 |
| Disease control rate (DCR) using RECIST v1.1 assessed by the investigator | Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study | Investigator-assessed DCR as per RECIST v1.1 |
Countries
United States
Outcome results
None listed